

Title (en)
LFA-3 AS A VACCINE ADJUVANT

Publication
EP 0463157 A4 19920603 (EN)

Application
EP 91904441 A 19910124

Priority
US 46914090 A 19900124

Abstract (en)
[origin: WO9111194A1] Vaccines comprising an immunogen and, as an adjuvant, LFA-3 or a fragment of LFA-3 capable of binding to CD2, a surface receptor on T-lymphocytes, are disclosed. LFA-3 has been found to markedly enhance the proliferation of activated T-cells and thus is capable of augmenting the immune response. Methods of vaccination in which LFA-3 is employed in conjunction with an immunogenic inoculum are also disclosed.

IPC 1-7
A61K 37/02; **A61K 39/00**

IPC 8 full level
A61K 39/29 (2006.01); **A61K 39/39** (2006.01); **A61K 39/395** (2006.01); **C07K 14/705** (2006.01)

CPC (source: EP)
A61K 39/12 (2013.01); **A61K 39/292** (2013.01); **A61K 39/39** (2013.01); **A61K 39/395** (2013.01); **C07K 14/70528** (2013.01); **A61K 2039/55516** (2013.01); **C12N 2730/10134** (2013.01); **Y02A 50/30** (2017.12)

Citation (search report)
• [X] WO 8912458 A1 19891228 - CELL MED INC [US]
• [X] WO 8910938 A1 19891116 - DANA FARBER CANCER INST INC [US]
• [X] CHEMICAL ABSTRACTS, vol. 108, no. 11, 14th March 1988, page 502, abstract no. 92752w, Columbus, Ohio, US; G. TIEFENTHALER et al.: "Purified lymphocyte function-associated antigen-3 and T11 target structure are active in CD2-mediated T cell stimulation" & EUR. J. IMMUNOL. 1987, 17(12), 1847-50
• See references of WO 9111194A1

Designated contracting state (EPC)
AT BE CH DE DK ES FR GB IT LI LU NL SE

DOCDB simple family (publication)
WO 9111194 A1 19910808; AU 7300091 A 19910821; CA 2049931 A1 19910725; EP 0463157 A1 19920102; EP 0463157 A4 19920603; JP H04506666 A 19921119

DOCDB simple family (application)
US 9100508 W 19910124; AU 7300091 A 19910124; CA 2049931 A 19910124; EP 91904441 A 19910124; JP 50484891 A 19910124